Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE SR versus THEO 24.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE SR versus THEO 24.
AEROLATE SR vs THEO-24
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (cAMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Theophylline, a xanthine derivative, acts as a non-selective phosphodiesterase (PDE) inhibitor (primarily PDE3 and PDE4), increasing intracellular cAMP and cGMP in airway smooth muscle and inflammatory cells. It also antagonizes adenosine receptors (A1, A2), stimulates endogenous catecholamine release, and may enhance histone deacetylase activity, reducing inflammation.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
300-600 mg orally once daily, extended-release capsule; individualize based on serum theophylline concentration targeting 5-15 mcg/mL.
None Documented
None Documented
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Terminal elimination half-life is approximately 3–8 hours in adults (non-smokers), 4–5 hours in smokers (due to enzyme induction), and highly variable in neonates (24–36 hours) and children (1–9 hours). Half-life is prolonged in cirrhosis (up to 30 hours), heart failure, and with concomitant medications (e.g., cimetidine, erythromycin).
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Approximately 90% of theophylline is eliminated hepatically via metabolism (principally CYP1A2 and CYP3A4), with less than 10% excreted unchanged in urine. Renal excretion of unchanged drug is minimal (about 5%) in adults. Biliary/fecal excretion accounts for less than 1%.
Category C
Category C
Bronchodilator
Bronchodilator